BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Stock
Equities
603392
CNE100004090
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.52 CNY | -0.14% |
|
+0.33% | -11.46% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 4.84B 670M | Sales 2025 * | 7.23B 1B | Capitalization | 84.48B 11.68B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.55B 353M | Net income 2025 * | 3.47B 479M | EV / Sales 2024 * | 16.3 x |
| Net cash position 2024 * | 5.27B 729M | Net cash position 2025 * | 5.25B 727M | EV / Sales 2025 * | 11 x |
| P/E ratio 2024 * |
37.7
x | P/E ratio 2025 * |
27.6
x | Employees | 3,843 |
| Yield 2024 * |
0.22% | Yield 2025 * |
0.28% | Free-Float | 18.23% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.03% | ||
| 1 week | +0.47% | ||
| Current month | -2.45% | ||
| 1 month | -0.16% | ||
| 3 months | +9.68% | ||
| 6 months | +37.06% | ||
| Current year | -11.34% |
1 week
65.40
67.37
1 month
63.0070.81
Current year
47.6288.00
1 year
40.1488.00
3 years
40.14147.67
5 years
4.43147.67
10 years
4.43147.67
| Managers | Title | Age | Since |
|---|---|---|---|
Yi Yong Zhao
DFI | Director of Finance/CFO | 53 | 07-12-31 |
Zi Xin Qiu
CHM | Chairman | 60 | 96-12-31 |
Hao Chen
ADM | Chief Administrative Officer | 42 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zi Xin Qiu
CHM | Chairman | 60 | 96-12-31 |
| 66 | - | ||
Qing Chao Xing
CHM | Chairman | 39 | 18-04-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.43% | 2 M€ | -12.23% | - | |
| 0.93% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-19 | 66.52 | -0.14% | 3 135 717 |
| 24-05-17 | 66.61 | +1.03% | 2,491,434 |
| 24-05-16 | 65.93 | -0.15% | 2,871,096 |
| 24-05-15 | 66.03 | -1.83% | 2,304,215 |
| 24-05-14 | 67.26 | +2.69% | 4,089,867 |
End-of-day quote Shanghai S.E., May 16, 2024
More quotes
Beijing Wantai Biopharmaceutical Co., Ltd. is a company mainly engaged in the research and development, production and sales of in-vitro diagnostics. The Company produces and sells in-vitro diagnostics, in-vitro diagnostic equipment and vaccines. The Company is also engaged in the sales of agent products. The in-vitro diagnostics include: enzyme-linked immunosorbent assay (ELISA) reagents, chemiluminescence reagents, biochemical reagents and quality control products. The in-vitro diagnostic instruments mainly include the automatic chemiluminescence immunoassay analyzer. The primary product of vaccine products is Hecolin used for hepatitis E. The agent products are in-vitro diagnostics and in-vitro diagnostic equipment from Bio-Rad Laboratories Inc in the U.S. and Diagast SAS in France.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
66.61
CNY
Average target price
70.4
CNY
Spread / Average Target
+5.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.34% | 11.7B | |
| -2.84% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| +58.05% | 25.73B | |
| -19.56% | 14.73B | |
| -9.06% | 12.82B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B | |
| -6.67% | 8.35B |
- Stock Market
- Equities
- 603392 Stock
